Glenmark gets approval for marketing two products in US
Posted AtThe Hindu Businessline
MUMBAI: Pharmaceutical firm
Glenmark on Friday said that it has received ANDA
approval for its anti-inflammatory and anti-diabetic
drugs and will soon commence marketing and distribution
of these products in the US market.
Glenmark Generics Ltd (GGL),
a subsidiary of Glenmark Pharmaceuticals, has received
the ANDA approval for Mometasone Furoate Ointment,
Mometasone Furoate Cream and Metformin Hydrochloride
tablets, the company said in a filing to the BSE.
GGL now has a portfolio of
32 generic products for the US market and over 35
ANDAs awaiting USFDA approval process. The total sales
for the two Mometasone Furoate products in the 12-month
period ending March 31, 2008 were over $29 million,
while, Metform in Hydrochloride used in the treatment
of diabetics had a total sales of over $158 million
for the year ended March 31, 2008 as per IMS Health.
Mometasone would be manufactured
at Glenmark's USFDA approved Baddi unit in Himachal
Pradesh. GGL had earlier acquired the US manufacturing
rights for a line of Chobetasol Propionate dermatology
products through a US-based pharmaceutical development
com pany. Shares of the company were trading at Rs
681, down 0.01 per cent on BSE in afternoon trade.
- PTI
May 30, 2008 |
